Colossal valuation, funding and investors
Colossal works in genome editing and de-extinction services, based in Austin, United States. Founded in 2021, it has about 266 employees.
- Last round
- Series C · $200M · Jan 2025
- Valuation at last round
- $10.20B
- Headcount
- 266 · up
- Grade
- B
- Founded
- 2021
Colossal valuation today
VCMC values Colossal at $14.4B today, with a range of $8.6B to $16.6B and a grade of B. The valuation starts from its last funding round, a Series C round in Jan 2025.
Valuation by date (74 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2021 | $17.1M | $6.21M – $46.9M | $19.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2021 | $17.2M | $6.27M – $47.3M | $19.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2021 | $17.4M | $6.32M – $47.7M | $19.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2021 | $17.5M | $6.38M – $48.2M | $19.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2021 | $83.3M | $54.8M – $254M | $167M (+100%) | after a round | – | unknown | C | 0% |
| 2 May 2021 | $83.5M | $54.8M – $254M | $167M (+100%) | after a round | – | unknown | C | 0% |
| 1 Jun 2021 | $88.4M | $54.8M – $254M | $167M (+89%) | after a round | – | unknown | C | 0% |
| 1 Jul 2021 | $93.6M | $54.8M – $254M | $167M (+78%) | after a round | – | unknown | C | 0% |
| 1 Aug 2021 | $99.2M | $54.8M – $254M | $167M (+68%) | after a round | – | unknown | C | 0% |
| 1 Sep 2021 | $105M | $54.8M – $254M | $167M (+58%) | after a round | – | unknown | C | 0% |
| 1 Oct 2021 | $111M | $54.8M – $254M | $167M (+50%) | after a round | – | unknown | C | 0% |
| 1 Nov 2021 | $118M | $54.8M – $254M | $167M (+41%) | after a round | – | unknown | C | 0% |
| 1 Dec 2021 | $125M | $54.8M – $254M | $167M (+33%) | after a round | – | unknown | C | 0% |
| 1 Jan 2022 | $133M | $54.8M – $254M | $167M (+26%) | after a round | – | unknown | C | 0% |
| 1 Feb 2022 | $141M | $54.8M – $254M | $167M (+18%) | after a round | – | unknown | C | 0% |
| 1 Mar 2022 | $148M | $54.8M – $254M | $167M (+12%) | after a round | 46 | unknown | C | 0% |
| 10 Mar 2022 | $261M | $183M – $665M | $468M (+80%) | after a round | 46 | unknown | C | 0% |
| 1 Apr 2022 | $270M | $183M – $665M | $468M (+73%) | after a round | 46 | unknown | C | 0% |
| 1 May 2022 | $283M | $183M – $665M | $468M (+65%) | after a round | 46 | unknown | C | 0% |
| 1 Jun 2022 | $298M | $183M – $665M | $468M (+57%) | after a round | 46 | unknown | C | 0% |
| 1 Jul 2022 | $313M | $183M – $665M | $468M (+50%) | after a round | 46 | unknown | C | 0% |
| 1 Aug 2022 | $329M | $183M – $665M | $468M (+43%) | after a round | 46 | unknown | C | 0% |
| 1 Sep 2022 | $345M | $183M – $665M | $468M (+36%) | after a round | 46 | unknown | C | 0% |
| 1 Oct 2022 | $362M | $183M – $665M | $468M (+29%) | after a round | 46 | unknown | C | 0% |
| 1 Nov 2022 | $381M | $183M – $665M | $468M (+23%) | after a round | 46 | unknown | C | 0% |
| 1 Dec 2022 | $400M | $183M – $665M | $468M (+17%) | after a round | 46 | unknown | C | 0% |
| 1 Jan 2023 | $481M | $217M – $785M | $553M (+15%) | after a round | 98 | growing | C | 0% |
| 1 Feb 2023 | $851M | $599M – $1.8B | $1.3B (+50%) | after a round | 98 | growing | B | 0% |
| 1 Mar 2023 | $878M | $599M – $1.8B | $1.3B (+45%) | after a round | 98 | growing | B | 0% |
| 1 Apr 2023 | $908M | $599M – $1.8B | $1.3B (+40%) | after a round | 98 | growing | B | 0% |
| 1 May 2023 | $939M | $599M – $1.8B | $1.3B (+36%) | after a round | 98 | growing | B | 0% |
| 1 Jun 2023 | $972M | $599M – $1.8B | $1.3B (+31%) | after a round | 98 | growing | B | 0% |
| 1 Jul 2023 | $1.0B | $599M – $1.8B | $1.3B (+27%) | after a round | 98 | growing | B | 0% |
| 1 Aug 2023 | $1.0B | $599M – $1.8B | $1.3B (+23%) | after a round | 98 | growing | B | 0% |
| 1 Sep 2023 | $1.1B | $599M – $1.8B | $1.3B (+18%) | after a round | 98 | growing | B | 0% |
| 1 Oct 2023 | $1.2B | $658M – $2.0B | $1.4B (+18%) | after a round | 150 | growing | B | 0% |
| 1 Nov 2023 | $1.2B | $658M – $2.0B | $1.4B (+13%) | after a round | 150 | growing | B | 0% |
| 1 Dec 2023 | $1.3B | $658M – $2.0B | $1.4B (+9%) | after a round | 150 | growing | B | 0% |
| 1 Jan 2024 | $1.3B | $658M – $2.0B | $1.4B (+4%) | after a round | 150 | growing | B | 0% |
| 1 Feb 2024 | $1.4B | $658M – $2.0B | $1.4B (0%) | after a round | 150 | growing | B | 0% |
| 1 Mar 2024 | $1.4B | $675M – $2.0B | $1.4B (0%) | after a round | 160 | growing | B | 0% |
| 1 Apr 2024 | $1.4B | $683M – $2.0B | $1.4B (0%) | after a round | 160 | growing | B | 0% |
| 1 May 2024 | $1.4B | $691M – $2.0B | $1.4B (0%) | after a round | 160 | growing | B | 0% |
| 1 Jun 2024 | $1.4B | $699M – $2.0B | $1.4B (0%) | after a round | 160 | growing | B | 0% |
| 1 Jul 2024 | $1.4B | $708M – $2.0B | $1.4B (0%) | after a round | 160 | growing | B | 0% |
| 1 Aug 2024 | $1.5B | $662M – $2.1B | $1.5B (0%) | after a round | 180 | up | B | 0% |
| 1 Sep 2024 | $1.5B | $658M – $2.1B | $1.5B (0%) | after a round | 180 | up | B | 0% |
| 1 Oct 2024 | $1.5B | $654M – $2.1B | $1.5B (0%) | after a round | 180 | up | B | 0% |
| 1 Nov 2024 | $1.5B | $651M – $2.1B | $1.5B (0%) | after a round | 180 | up | B | 0% |
| 1 Dec 2024 | $1.5B | $647M – $2.1B | $1.5B (0%) | after a round | 180 | up | B | 0% |
| 1 Jan 2025 | $1.5B | $643M – $2.1B | $1.5B (0%) | after a round | 180 | up | B | 0% |
| 18 Jan 2025 | $10.2B | $8.9B – $15.3B | $13.3B (+30%) | after a round | 180 | up | A | 0% |
| 1 Feb 2025 | $10.3B | $8.9B – $15.3B | $13.3B (+29%) | after a round | 180 | up | A | 0% |
| 1 Mar 2025 | $10.5B | $8.9B – $15.3B | $13.3B (+26%) | after a round | 180 | up | A | 0% |
| 1 Apr 2025 | $10.8B | $8.9B – $15.3B | $13.3B (+23%) | after a round | 180 | up | A | 0% |
| 1 May 2025 | $11.0B | $8.9B – $15.3B | $13.3B (+21%) | after a round | 180 | up | A | 0% |
| 1 Jun 2025 | $11.2B | $8.9B – $15.3B | $13.3B (+18%) | after a round | 180 | up | A | 0% |
| 1 Jul 2025 | $11.5B | $8.9B – $15.3B | $13.3B (+15%) | after a round | 180 | up | A | 0% |
| 1 Aug 2025 | $11.7B | $8.9B – $15.3B | $13.3B (+13%) | after a round | 180 | up | A | 0% |
| 1 Sep 2025 | $12.0B | $8.9B – $15.3B | $13.3B (+10%) | after a round | 180 | up | A | 0% |
| 1 Oct 2025 | $12.3B | $8.9B – $15.3B | $13.3B (+8%) | after a round | 180 | flat | A | 0% |
| 1 Nov 2025 | $12.9B | $8.9B – $15.9B | $13.8B (+7%) | after a round | 216 | up | A | 0% |
| 1 Dec 2025 | $13.3B | $8.9B – $15.9B | $13.8B (+4%) | after a round | 216 | up | A | 0% |
| 1 Jan 2026 | $13.6B | $8.9B – $15.9B | $13.8B (+1%) | after a round | 216 | up | A | 0% |
| 1 Feb 2026 | $13.8B | $8.8B – $15.9B | $13.8B (0%) | after a round | 216 | up | A | 0% |
| 1 Mar 2026 | $13.8B | $8.8B – $15.9B | $13.8B (0%) | after a round | 216 | up | A | 0% |
| 1 Apr 2026 | $13.8B | $8.7B – $15.9B | $13.8B (0%) | after a round | 216 | up | B | 0% |
| 1 May 2026 | $13.8B | $8.6B – $15.9B | $13.8B (0%) | after a round | 216 | up | B | 0% |
| 1 Jun 2026 | $14.3B | $8.7B – $16.4B | $14.3B (0%) | after a round | 252 | up | B | 0% |
| 1 Jul 2026 | $14.3B | $8.6B – $16.4B | $14.3B (0%) | after a round | 252 | up | B | 0% |
| 1 Aug 2026 | $14.4B | $8.6B – $16.6B | $14.4B (0%) | after a round | 263 | up | B | 0% |
| 1 Sep 2026 | $14.4B | $8.6B – $16.6B | $14.4B (0%) | after a round | 263 | up | B | 0% |
| 1 Oct 2026 | $14.4B | $8.6B – $16.6B | $14.4B (0%) | after a round | 266 | up | B | 0% |
| 24 Oct 2026 | $14.4B | $8.6B – $16.6B | $14.4B (0%) | after a round | 266 | up | B | 0% |
Key facts about Colossal
- Founded
- 2021
- Headquarters
- Austin, United States
- Employees
- about 266 +23% in a year
- Total raised
- $425M
- Funding rounds
- 5
- Last round
- Series C Jan 2025
Colossal was founded in 2021 by Ben Lamm and George Church.
Colossal funding history
Colossal has 5 funding rounds on record, from May 2021 to Jan 2025, $425M in total. The latest disclosed valuation is $10.20B post-money (Series C, Jan 2025).
Series C 17 Jan 2025
Led by TWG Global.
Sources: techfundingnews.com, colossal.com, techcrunch.com and 2 more
$200M
$10.20B post-money
Series B 31 Jan 2023
Led by United States Innovative Technology, Breyer Capital; with WestRiver Group, Animal Capital, In-Q-Tel, Animoca Brands, PEAK6, BOLD Capital Partners, JAZZ Venture Partners.
Sources: finsmes.com, pharmalive.com, gunder.com and 1 more
$150M
Grant 1 Oct 2022no round page
Investors not disclosed.
Amount undisclosed
Series A 9 Mar 2022
Led by At One Ventures; with Untamed Planet, Animoca Brands, Breyer Capital, Animal Capital, ARCH Venture Partners, BOLD Capital Partners, First Light Capital Group, Boost VC, JAZZ Venture Partners, Builders VC, Green Sands Equity, Draper Associates.
Sources: finsmes.com, colossal.com, research.contrary.com
$60M
$15M
Colossal investors
19 investors have backed Colossal; Breyer Capital, At One Ventures and Thomas Tull and 2 more led at least one round.
- Breyer Capital lead, 2 rounds
- At One Ventures lead
- Thomas Tull lead
- Animoca Brands 2 rounds
- ARCH Venture Partners
- First Light Capital Group
- In-Q-Tel
- Untamed Planet
What Colossal does
Colossal works in biotechnology, with 12 recorded offerings and customers in biotechnology and conservation biology.
Colossal Biosciences Inc. is an American biotechnology company engaged in genetic engineering and reproductive technology for conservation biology. The company focuses on de-extinction efforts, including the resurrection of extinct species such as the Woolly Mammoth and the Thylacine, and operates globally, collaborating with conservation partners and universities. Colossal also engages in genome projects and research initiatives related to rewilding and ecosystem restoration.
Description from Veridion's company data.
Products and services
- Genome Editing and De-Extinction Services
- Conservation Genetics Research and Development
- Reproductive Technology Development for Conservation
- Biosciences Research and Innovation
- Genomic Data Analysis and Application
- Ecosystem Restoration and Rewilding Solutions
- Animal Hybrid Breeding and Reproduction
- Captive Population Management Services
- Habitat Reintroduction Planning and Execution
- Academic and Conservation Partnership Development
- Ethical and Responsible Science Stewardship
- Sustainable Biosciences Development
Markets
- Biotechnology
- Conservation Biology
Technology
- CRISPR-Cas9 Gene Editing
Business model
- Business-to-Business
- Enterprise
Industry codes (NAICS)
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match
Questions about Colossal
What is Colossal worth?
Valuation $14.4B (range $8.6B to $16.6B), as of 24 Oct 2026. The last disclosed valuation was $10.20B (Series C, Jan 2025).
Has Colossal raised money?
Colossal has 5 funding rounds on record, from May 2021 to Jan 2025, $425M in total. The latest disclosed valuation is $10.20B post-money (Series C, Jan 2025).
Who has invested in Colossal?
Breyer Capital, At One Ventures, Thomas Tull, TWG Global, United States Innovative Technology and Animal Capital, and 13 more. Lead investors include Breyer Capital, At One Ventures, Thomas Tull and TWG Global.
How many people work at Colossal?
About 266, up 23% over the last year. Headcount grew from 46 in Mar 2022 to 266 in Sep 2026.
What does Colossal do?
Colossal works in biotechnology, with 12 recorded offerings and customers in biotechnology and conservation biology. Its main offerings are genome editing and de-extinction services, conservation genetics research and development and reproductive technology development for conservation.
When was Colossal founded, and where is it based?
Colossal was founded in 2021 and is based in Austin, United States. It has about 266 employees, up 23% over the last year.